Phacilitate Leaders Forum

Speakers

Loading
Mark Flower

Mark Flower

Vice President, Business Development and Strategic Partnerships , Be The Match BioTherapies

Mark Flower is the Vice President of Business Development and Strategic Partnerships for Be The Match BioTherapies.

He is responsible for aligning the organization’s objectives with a firm business strategy, overseeing research and development of new markets for the organization’s products and services, proactively assessing existing sales organization support investments, and leading development initiatives to grow sales and new business development for the organization.

Flower brings more than 12 years of experience working in the field of immuno-oncology, cell based gene and immunotherapy, cell therapy manufacturing and bioprocessing. Previously, he served as the Executive Director of Sales and Marketing at Hitachi Chemical Advanced Therapeutics Solutions, and as Senior Manager, Global Strategic Marketing, in the Therapeutic Systems business unit at Terumo BCT. In those roles he lead both sales and marketing teams, and successfully launched multiple devices and technologies in the field of stem cell collection via leukapheresis, cell isolation, cell processing and culture. His relationships extend from commercial cell therapy developers to leading academic and research centers that serve as the clinical trial sites for numerous innovative cell therapies.

Flower is a member of the International Society for Cell and Gene Therapy (ISCT) and the Society for Immunotherapy of Cancer (SITC). He graduated from the University of California, San Diego with a B.S. in Biological Sciences.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd